The Imperative of Responsible Innovation in Reproductive Medicine

Sebastiaan Mastenbroek, Guido de Wert, Eli Y. Adashi · 2021 · New England Journal of Medicine

Summary. This article examines the lack of evidence supporting widespread use of preimplantation genetic testing for aneuploidy in reproductive medicine. The authors use this case to highlight a broader problem: reproductive medicine adopts new technologies without sufficient data demonstrating their safety and effectiveness. They argue for more responsible innovation practices that require robust evidence before clinical implementation.

Read the original

Cite this article

Mastenbroek, S., Wert, G. D., & Adashi, E. Y.. (2021). The Imperative of Responsible Innovation in Reproductive Medicine. New England Journal of Medicine. https://doi.org/10.1056/nejmsb2101718

@article{mastenbroek-2021-imperative-responsible-innovation-reproductive-medicine,
  title   = {The Imperative of Responsible Innovation in Reproductive Medicine},
  author  = {Sebastiaan Mastenbroek and Guido de Wert and Eli Y. Adashi},
  journal = {New England Journal of Medicine},
  year    = {2021},
  doi     = {10.1056/nejmsb2101718},
  url     = {https://doi.org/10.1056/nejmsb2101718}
}

TY  - JOUR
TI  - The Imperative of Responsible Innovation in Reproductive Medicine
AU  - Sebastiaan Mastenbroek
AU  - Guido de Wert
AU  - Eli Y. Adashi
JO  - New England Journal of Medicine
PY  - 2021
DO  - 10.1056/nejmsb2101718
UR  - https://doi.org/10.1056/nejmsb2101718
ER  -

Details

DOI: 10.1056/nejmsb2101718
Countries: Netherlands, United States
Regions: Europe, North America
Categories: innovation-theory, general-innovation
Added: 2026-04-28